Skip to Main Content

Paper Details

BET Inhibitors Suppress ALDH Activity by Targeting ALDH1A1 Super-Enhancer in Ovarian Cancer.
Cancer Res
105
2016
-treated, ALDH, ALDH1A1, ALDH1A1 Super-Enhancer, BET, BET protein, BRD4, JQ1, Ovarian Cancer, aldehyde, aldehyde dehydrogenase, associated enhancer RNA, bromodomain, cisplatin, cisplatin-treated ovarian cancer cells, mice, ovarian cancer, ovarian cancer cells, promoter regions, stem-related genes, super-enhancer element, tumor, tumor cells
Author NameAffiliation
Andrew V KossenkovCenter for Systems and Computational Biology, The Wistar Institute
Louise C ShoweCenter for Systems and Computational Biology, The Wistar Institute
Louise C ShoweThe Wistar Institute
David W SpeicherThe Wistar Institute
James E BradnerDana-Farber Cancer Institute, Harvard Medical School
Zhiguo ZhangMayo Clinic
Zhiguo ZhangMayo Clinic
Anil K SoodThe University of Texas MD Anderson Cancer Center
Anil K SoodCenter for RNAi and Non-Coding RNA, The University of Texas MD Anderson Cancer Center
Anil K SoodThe University of Texas MD Anderson Cancer Center
  • 1 - 10

Datasets

Release 1.2